174 related articles for article (PubMed ID: 17062838)
41. Paricalcitol in secondary hyperparathyroidism and the survival benefit in patients with chronic kidney disease.
Al-Baaj F; Yadav P; Al-Rifai A
J Ren Care; 2011 Jun; 37(2):75-9. PubMed ID: 21561542
[TBL] [Abstract][Full Text] [Related]
42. Spotlight on paricalcitol in secondary hyperparathyroidism.
Robinson DM; Scott LJ
Treat Endocrinol; 2005; 4(3):185-6. PubMed ID: 15898824
[TBL] [Abstract][Full Text] [Related]
43. Cardiovascular disease in chronic kidney failure: the role of VDR activators.
Wu-Wong JR; Tian J; Nakane M; Ma J; Fey TA; Kroeger P; Fryer RM; Reinhart GA
Curr Opin Investig Drugs; 2006 Mar; 7(3):206-13. PubMed ID: 16555680
[TBL] [Abstract][Full Text] [Related]
44. Effect of doxercalciferol (1alpha-hydroxyvitamin D2) on PTH, bone turnover and bone mineral density in a hemodialysis patient with persistent secondary hyperparathyroidism post parathyroidectomy.
Parisi MS; Oliveri B; Somoza J; Mautalen C
Clin Nephrol; 2003 Jun; 59(6):471-4. PubMed ID: 12834181
[TBL] [Abstract][Full Text] [Related]
45. Paricalcitol capsules for the control of secondary hyperparathyroidism in chronic kidney disease.
Cheng S; Coyne D
Expert Opin Pharmacother; 2006 Apr; 7(5):617-21. PubMed ID: 16553577
[TBL] [Abstract][Full Text] [Related]
46. Highly concentrated calcitriol and its analogues induce apoptosis of parathyroid cells and regression of the hyperplastic gland--study in rats.
Shiizaki K; Hatamura I; Negi S; Sakaguchi T; Saji F; Imazeki I; Kusano E; Shigematsu T; Akizawa T
Nephrol Dial Transplant; 2008 May; 23(5):1529-36. PubMed ID: 18156462
[TBL] [Abstract][Full Text] [Related]
47. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study.
Fadem SZ; Al-Saghir F; Zollner G; Swan S
Clin Nephrol; 2008 Oct; 70(4):319-24. PubMed ID: 18826857
[TBL] [Abstract][Full Text] [Related]
48. Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol.
Hernandez JD; Wesseling K; Boechat MI; Gales B; Salusky IB
Nat Clin Pract Nephrol; 2007 Apr; 3(4):227-32. PubMed ID: 17389892
[TBL] [Abstract][Full Text] [Related]
49. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
50. Bone disease in uremic patients: advances in PTH suppression.
Brancaccio D; Cozzolino M; Gorio A; Di Giulio AM; Gallieni M
J Nephrol; 2002; 15 Suppl 6():S86-93. PubMed ID: 12515379
[TBL] [Abstract][Full Text] [Related]
51. Paricalcitol treatment of secondary hyperparathyroidism in hemodialysis patients on sevelamer hydrochloride: which dialysate calcium concentration to use?
Sonikian M; Metaxaki P; Karatzas I; Vlassopoulos D
Blood Purif; 2009; 27(2):182-6. PubMed ID: 19141997
[TBL] [Abstract][Full Text] [Related]
52. Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients.
Drüeke TB; Landais P
Am J Kidney Dis; 2006 Jun; 47(6):1083; author reply 1083-4. PubMed ID: 16731305
[No Abstract] [Full Text] [Related]
53. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
54. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism.
Felsenfeld AJ; Rodríguez M; Aguilera-Tejero E
Clin J Am Soc Nephrol; 2007 Nov; 2(6):1283-305. PubMed ID: 17942777
[TBL] [Abstract][Full Text] [Related]
55. Paricalcitol: a review of its use in the management of secondary hyperparathyroidism.
Robinson DM; Scott LJ
Drugs; 2005; 65(4):559-76. PubMed ID: 15733015
[TBL] [Abstract][Full Text] [Related]
56. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD.
Kooienga L; Fried L; Scragg R; Kendrick J; Smits G; Chonchol M
Am J Kidney Dis; 2009 Mar; 53(3):408-16. PubMed ID: 19185400
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone.
Upton RA; Knutson JC; Bishop CW; LeVan LW
Nephrol Dial Transplant; 2003 Apr; 18(4):750-8. PubMed ID: 12637645
[TBL] [Abstract][Full Text] [Related]
58. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs.
Brancaccio D; Cozzolino M; Galassi A; Chiarelli G; Butti A; Bellasi A; Rocca-Rey L; Volpi A; Anelli A; Zoni U; Fusaro M; Brambilla C; Missaglia E; Crovetto C; Russo M; Longhini C; Provenzano R; Incalcaterra F; Cerasola G; Li Vecchi M; Gallieni M
J Nephrol; 2007; 20(1):3-9. PubMed ID: 17347966
[TBL] [Abstract][Full Text] [Related]
59. Combination vitamin D therapy in stage 5 chronic kidney disease.
Vondracek SF; Hoody DW
Ann Pharmacother; 2011 Jul; 45(7-8):1011-5. PubMed ID: 21750312
[TBL] [Abstract][Full Text] [Related]
60. Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism.
Mansour J; Shahapuni I; Mailliez S; Aghai R; Fournier A
Nat Clin Pract Nephrol; 2007 Apr; 3(4):E2; discussion E3. PubMed ID: 17389886
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
